Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Third Quarter 2022 Financial Results
07 nov. 2022 16h01 HE | FibroGen, Inc.
Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024Completed enrollment of MATTERHORN Phase 3 study of roxadustat...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Participate at Stifel 2022 Healthcare Conference
01 nov. 2022 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022...
PRPO logo.png
Precipio Launches New 1-Step Technology for all HemeScreen Assays
16 août 2022 11h00 HE | Precipio, Inc.
NEW HAVEN, Conn., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its second generation of HemeScreen panels. Precipio’s...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Second Quarter 2022 Financial Results
25 juil. 2022 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also...
TIP_link_300x300.jpg
Blood Temperature Indicator Market Worth $504.37 Mn, Globally, by 2028 at 12.9% CAGR - Exclusive Report by The Insight Partners
18 mai 2022 08h58 HE | The Insight Partners
New York, May 18, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Blood Temperature Indicator Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by...
PRPO logo.png
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
26 avr. 2022 10h00 HE | Precipio, Inc.
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen,...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
28 févr. 2022 16h01 HE | FibroGen, Inc.
Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results
14 févr. 2022 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close....
Image
Nemysis Ltd Announces Appointment of Antonino Santoro as Adviser for Scientific Affairs
07 févr. 2022 04h30 HE | Nemysis Limited
DUBLIN, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Nemysis Ltd today announces the appointment of Antonino Santoro to its Executive Team as Adviser for Scientific Affairs. Antonino Santoro is a Chemist,...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
04 janv. 2022 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C....